Closing the Earnings Gap
Executive SummaryAccording to Boston Consulting Group, patent expirations and market pressures mean that the existing pipeline of drugs will generate an average of only 5.5% annual earnings growth--less than half the 13% necessary to meet shareholder expectations. To grow earnings at the required rate, companies need to pursue a combination of new product strategies, improving margins through cost reductions and growing existing products.
You may also be interested in...
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
No device-related warning letters were released by the US FDA the week of 10 December.